Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203020 · ClinicalTrials.gov registry record · Phase 2
Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
A Phase 2 study of Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma, sponsored by West Virginia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT01203020 is a Phase 2 study of Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma that has completed, run by West Virginia University. The registered enrollment target is 22 participants, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01203020, a Phase 2 study of Non-Hodgkin's Lymphoma and Hodgkin's Lymphoma, has completed, sponsored by West Virginia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study of allogeneic hematopoietic progenitor cell transplantation (HPCT) followed reduced toxicity conditioning with once daily intravenous Busulfex and fludarabine in patients with relapsed/chemotherapy refractory Hodgkin's and non-Hodgkin's lymphomas.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
Study Locations (1)
West Virginia
- West Virginia University Hospitals Mary Babb Randolph Cancer Center - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-10-12 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01203020
The ClinicalTrials.gov registry entry for NCT01203020 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Fludarabine is the first listed.
NCT01203020 reports 1 study location spanning 1 distinct geographic area - top geographies include West Virginia.
Frequently Asked Questions
What is clinical trial NCT01203020 about?
NCT01203020 is a clinical study titled "Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation". This is a phase II study of allogeneic hematopoietic progenitor cell transplantation (HPCT) followed reduced toxicity conditioning with once daily intravenous Busulfex and fludarabine in patients with relapsed/chemotherapy refractory Hodgkin's and non-Hodgkin's lymphomas.
What is the current status of trial NCT01203020?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2010-10-12. Estimated completion is 2021-09-27.
What conditions does trial NCT01203020 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01203020?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG).
Who is sponsoring clinical trial NCT01203020?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01203020 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.